Analyst Conference Summary |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
biotechnology
|
Amgen
|
Product sales $ millions |
Q1 2024 |
Q4 2023 |
Q1 2023 |
y/y % |
Prolia | $ |
$1,107 |
$ |
% |
Repatha | 417 |
% |
||
Aimovig | 78 |
% |
||
Evenity | 318 |
% |
||
Lumakras | 77 |
% |
||
Neulasta | 239 |
% |
||
Otezla | 629 |
% |
||
Epogen | 55 |
% |
||
Enbrel | 1,015 |
% |
||
Arenesp | 319 |
% |
||
Vectibix | 251 |
% |
||
Nplate | 386 |
% |
||
Xgeva | 527 |
% |
||
Kyprolis | 350 |
% |
||
Blincyto | 241 |
% |
||
Parsabiv | 89 |
% |
||
Tezspire | 177 |
% |
Tepezza | 448 |
na |
na |
Krystexxa | 272 |
na |
na |
Upliza | 65 |
na |
na |
Tavneos | 44 |
% |
||
Amgevita | 160 |
% |
||
Kanjinti | 42 |
% |
||
Mvasi | 188 |
% |
ultra rares | 164 |
na |
na |
other | 175 |
% |
Cash and equivalents balance ended at $ billion, down sequentially from $10.9 billion. Operating cash flow $ billion. Capital expenditures $ billion. Free cash flow was $ billion. At the end of quarter debt was $ billion. No shares were repurchased in the quarter. Dividend payments were $ billion.
See also the Amgen pipeline.
GAAP cost of sales was $ billion. Research and development expense was $ billion; selling general and administrative expense $ billion; and other operating expense $ million, for total operating expenses of $ billion. Operating income was $ billion. Interest expense was $ million, other income $ million, income taxes $ million.
Q&A selective summary:
More Analyst Conference Pages:
AGEN |
AGIO |
ALNY |
AMAT |
APRE |
ARWR |
BIIB |
BLRX |
BLUE |
BMY |
CDTX |
CLDX |
FATE |
GILD |
GLYC |
ILMN |
INCY |
INKT |
INO |
IONS |
MCHP |
MRNA |
PLX |
REGN |
RNA |
SAGE |
SANA |
SGEN |
SYRS |
TSVT |
VRTX |
VSTM |
WBA |
Disclaimer: My analyst call summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes that I use as the basis for my Seeking Alpha articles. They are not advice.
Copyright 2024 William P. Meyers